Management of diet in gastrointestinal cancer

Shaw, Clare

doi:10.1017/s0029665120007041

Cited by 19 publications

(17 citation statements)

References 53 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[20][21][22][23] Considering the higher prevalence of malnutrition and mood disorder in patients with EGC than in patients with other solid tumors, a feasible supportive care model adapted for metastatic EGC is urgently needed. 24,25 Therefore, we prospectively conducted a randomized controlled trial to compare the clinical benefits of early integration of interdisciplinary supportive care, which included nutritional and psychological support, with standard anticancer treatment in patients with previously untreated metastatic EGC.…”

Section: Appendix Protocolmentioning

confidence: 99%

Early Interdisciplinary Supportive Care in Patients With Previously Untreated Metastatic Esophagogastric Cancer: A Phase III Randomized Controlled Trial

Liu

et al. 2021

JCO

View full text Add to dashboard Cite

PURPOSE Effective interventions to improve prognosis in metastatic esophagogastric cancer (EGC) are urgently needed. We assessed the effect of the early integration of interdisciplinary supportive care for patients with metastatic EGC on overall survival (OS). PATIENTS AND METHODS An open-label, phase III, randomized, controlled trial was conducted at Peking University Cancer Hospital & Institute. Patients with previously untreated metastatic EGC were enrolled. Patients were randomly assigned (2:1) to either early interdisciplinary supportive care (ESC) integrated into standard oncologic care or standard care (SC). ESC was provided by a team of GI medical oncologists, oncology nurse specialists, dietitians, and psychologists; patients in the SC group received standard oncologic care alone. The primary end point was OS in the intention-to-treat population. RESULTS Between April 16, 2015, and December 29, 2017, 328 patients were enrolled: 214 in the ESC group and 114 in the SC group. At the data cutoff date of January 26, 2019, 15 (5%) patients were lost to follow-up. The median number of cycles of first-line chemotherapy was five (interquartile range [IQR], 4-7) in the ESC group and four (IQR, 2-6) in the SC group. The median OS was 14.8 months (95% CI, 13.3 to 16.3) in the ESC group and 11.9 months (95% CI, 9.6 to 13.6) in the SC group (hazard ratio, 0.68; 95% CI, 0.51 to 0.9; P = .021). CONCLUSION The early integration of interdisciplinary supportive care is an effective intervention with survival benefits for patients with metastatic EGC. Further optimization and standardization are warranted.

show abstract

Section: Appendix Protocolmentioning

confidence: 99%

Early Interdisciplinary Supportive Care in Patients With Previously Untreated Metastatic Esophagogastric Cancer: A Phase III Randomized Controlled Trial

Liu

et al. 2021

JCO

View full text Add to dashboard Cite

show abstract

“…Sarcopenia is characterized by generalized muscle mass loss and muscle functional decline, leading to physical frailty, cachexia, and mortality [ 1 , 2 ]. Malnutrition, reticence, advanced malignancy burden, and persistent inflammatory condition often identified in patients with gastrointestinal disorders are typical clinical characteristics associated with sarcopenia [ 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , 9 ]. Patients with advanced cancer are prone to muscle protein loss due to muscle proteolysis-inducing factors and inflammatory cytokines released by the cancer cells [ 10 ].…”

Section: Introductionmentioning

confidence: 99%

Prognostic Impact of the SARC-F Score in Gastrointestinal Advanced Cancers

Morimoto

Nishikawa

Goto

et al. 2021

Cancers

View full text Add to dashboard Cite

We sought to elucidate the prognostic impact of the SARC-F score among patients with gastrointestinal advanced malignancies (n = 421). A SARC-F score ≥ 4 was judged to have a strong suspicion for sarcopenia. In patients with ECOG-PS 4 (n = 43), 3 (n = 61), and 0–2 (n = 317), 42 (97.7%), 53 (86.9%) and 8 (2.5%) had the SARC-F score ≥ 4. During the follow-up period, 145 patients (34.4%) died. All deaths were cancer-related. The 1-year cumulative overall survival (OS) rate in patients with SARC-F ≥ 4 (n = 103) and SARC-F < 4 (n = 318) was 33.9% and 61.6% (p < 0.0001). In the multivariate analysis for the OS, total lymphocyte count ≥ 1081/μL (p = 0.0014), the SARC-F score ≥ 4 (p = 0.0096), Glasgow prognostic score (GPS) 1 (p = 0.0147, GPS 0 as a standard), GPS 2 (p < 0.0001, GPS 0 as a standard), ECOG-PS 2 (p < 0.0001, ECOG-PS 0 as a standard), ECOG-PS 3 (p < 0.0001, ECOG-PS 0 as a standard), and ECOG-PS 4 (p < 0.0001, ECOG-PS 0 as a standard) were independent predictors. In the receiver operating characteristic curve analysis on the prognostic value of the SARC-F score, the sensitivity/specificity was 0.59/0.70, and best cutoff point of the SARC-F score was two. In conclusion, the SARC-F score is useful in patients with gastrointestinal advanced malignancies.

show abstract

“…Sarcopenia is characterized by generalized loss of muscle mass and muscle functional decline, resulting in physical frailty, cachexia and mortality [1,2]. Malnutrition, reticence, advanced malignancy-bearing status and persistent inflammatory status frequently observed in gastrointestinal diseases (GDs) are representative features associated with sarcopenia [1][2][3][4][5][6][7][8][9]. Reduced daily dietary intakes and deterioration of nutritional status can be also often seen in patients with GDs [8], and sarcopenia in patients with GDs is associated with poorer patient quality of life (QOL) and prognosis [8,10].…”

Section: Introductionmentioning

confidence: 99%

The Relationship between the SARC-F Score and the Controlling Nutritional Status Score in Gastrointestinal Diseases

Ikegami

Nishikawa

Goto

et al. 2022

JCM

View full text Add to dashboard Cite

We sought to examine the relationship between the SARC-F score and the Controlling Nutritional Status (CONUT) score in patients with gastrointestinal diseases (GDs, n = 735, median age = 71 years, and 188 advanced cancer cases). The SARC-F score ≥ 4 (highly suspicious of sarcopenia) was found in 93 cases (12.7%). Mild malnutritional condition was seen in 310 cases (42.2%), moderate in 127 (17.3%) and severe in 27 (3.7%). The median SARC-F scores in categories of normal, mild, moderate and severe malnutritional condition were 0, 0, 1 and 1 (overall p < 0.0001). The percentage of SARC-F score ≥ 4 in categories of normal, mild, moderate and severe malnutritional condition were 4.4%, 12.9%, 26.8% and 25.9% (overall p < 0.0001). The SARC-F score was an independent factor for both the CONUT score ≥ 2 (mild, moderate or severe malnutrition) and ≥5 (moderate or severe malnutrition). In the receiver operating characteristic (ROC) curve analysis for the CONUT score ≥ 2, C reactive protein (CRP) had the highest area under the ROC (AUC = 0.70), followed by the SARC-F score (AUC = 0.60). In the ROC analysis for the CONUT score ≥ 5, CRP had the highest AUC (AUC = 0.79), followed by the SARC-F score (AUC = 0.63). In conclusion, the SARC-F score in patients with GDs can reflect malnutritional status.

show abstract

Management of diet in gastrointestinal cancer

Cited by 19 publications

References 53 publications

Early Interdisciplinary Supportive Care in Patients With Previously Untreated Metastatic Esophagogastric Cancer: A Phase III Randomized Controlled Trial

Early Interdisciplinary Supportive Care in Patients With Previously Untreated Metastatic Esophagogastric Cancer: A Phase III Randomized Controlled Trial

Prognostic Impact of the SARC-F Score in Gastrointestinal Advanced Cancers

The Relationship between the SARC-F Score and the Controlling Nutritional Status Score in Gastrointestinal Diseases

Contact Info

Product

Resources

About